Bailey Pemberton
3 min read
Price targets for Hikma Pharmaceuticals are currently clustered in the £1,870 to £2,100 range, which sits above the latest fair value estimate of £19.70. Analysts linking these higher targets to Hikma Pharmaceuticals point to confidence in execution and valuation, although they also flag sensitivity to assumptions that could work against the stock if conditions change. As you read on, you will see how to interpret this evolving narrative and what to watch as new research comes through.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Recent research on Hikma Pharmaceuticals has centered on higher price targets from Citi and Berenberg, which both maintain positive ratings and point to what they view as an appealing setup at current levels.
-
Citi initiated coverage on Hikma Pharmaceuticals in July 2026 with a Buy rating and a £17.00 price target and later raised this to £18.70, a move that signals continued confidence in the company’s ability to execute on its plan.
-
Berenberg adjusted its price target from £18.00 to £21.00 while keeping a Buy rating, which places the upper end of the current target range well above the latest fair value estimate cited earlier.
🐻 Bearish Takeaways
-
The clustering of Citi and Berenberg targets above the fair value estimate suggests that a portion of the upside case already relies on optimistic assumptions about Hikma Pharmaceuticals, which could work against the stock if sentiment or company specific news turn less supportive.
-
With only two firms currently in focus and both carrying Buy ratings, investors do not yet have a broad spread of views, so any change in tone from Citi or Berenberg could have an outsized impact on how the valuation story is perceived.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 2 risks for Hikma Pharmaceuticals. See which could impact your investment.
How This Changes the Fair Value For Hikma Pharmaceuticals
-
The fair value estimate for Hikma Pharmaceuticals increased from £18.74 to £19.70.
-
The revenue growth assumption decreased from 4.38% to 4.19%.
-
The profit margin assumption increased from 13.15% to 13.21%.
-
The future P/E assumption increased from 13.24x to 13.37x.
-
The discount rate increased from 7.38% to 7.56%.
Never Miss an Update: Follow The Narrative
